In this study, we determined the in vivo efficacy of mebendazole as a single agent therapy in two well-characterized transgenic mouse models of pancreatic cancer, the KC (KrasG12D), caerulein-induced model of PanIN progression and the KPC (KrasG12D/Tp53R172H) transgenic mouse model of advanced, metastatic PDAC. This evidence concerns the gene CALCA and pancreatic neoplasm.